The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature

…, M Podhola, S Rejchrt, M Minarik, L Benesova… - Gastrointestinal …, 2016 - Elsevier
Background and Aims Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
has to date been recognized in only 8 families worldwide. Recently, different point …

[HTML][HTML] MicroRNAs in pancreatic cancer: involvement in carcinogenesis and potential use for diagnosis and prognosis

…, R Cuperkova, M Minarik, L Benesova - … Research and Practice, 2015 - hindawi.com
Pancreatic cancer is one of the most fatal malignancies with increasing incidence and high
mortality. Possibilities for early diagnosis are limited and there is currently no efficient therapy…

[HTML][HTML] Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)–a helicobacter-opposite point

I Tacheci, R Repak, M Podhola, L Benesova… - Best Practice & …, 2021 - Elsevier
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare familial
gastric cancer syndrome with an autosomal dominant pattern of inheritance. It is characterised …

[HTML][HTML] Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration …

C Salek, L Benesova, M Zavoral, V Nosek… - World journal of …, 2007 - ncbi.nlm.nih.gov
AIM: To establish an optimum combination of molecular markers resulting in best overall
diagnostic sensitivity and specificity for evaluation of suspicious pancreatic mass. METHODS: …

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non …

O Fiala, M Pesek, J Finek, L Benesova, B Belsanova… - Cancer genetics, 2013 - Elsevier
The role of KRAS mutations in molecular targeted therapy by epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has not …

Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors

L Benesova, M Minarik, D Jancarikova… - Anticancer …, 2010 - ar.iiarjournals.org
Background: Concurrent presence of EGFR and KRAS mutations in non-small cell lung
cancer (NSCLC) patients is relatively rare and their appearance is believed to be mutually …

The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second-or third-line chemotherapy

…, M Pesek, Z Bortlicek, M Minarik, L Benesova… - Anticancer …, 2016 - ar.iiarjournals.org
Background/Aim: The prognostic and predictive value of Kirsten rat sarcoma viral oncogene
homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. …

[HTML][HTML] Monitoring of early changes of circulating tumor DNA in the plasma of rectal cancer patients receiving neoadjuvant concomitant chemoradiotherapy …

F Pazdirek, M Minarik, L Benesova, T Halkova… - Frontiers in …, 2020 - frontiersin.org
Introduction: Patients with locally advanced rectal cancer (LARC) are undergoing neoadjuvant
chemoradiotherapy (NCRT) prior to surgery. Although in some patients the NCRT is …

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib

O Fiala, M Pesek, J Finek, L Benesova… - Anticancer …, 2014 - ar.iiarjournals.org
Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients
with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction …

[HTML][HTML] Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

L Benešová, T Hálková, R Ptáčková… - World Journal of …, 2019 - ncbi.nlm.nih.gov
BACKGROUND One of the most notable applications for circulating tumor DNA (ctDNA)
detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term …